• 1. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 2. Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations
  Benjamin Gabriel Poulson,Kacper Szczepski,Joanna Izabela Lachowicz,Lukasz Jaremko,Abdul-Hamid Emwas,Mariusz Jaremko RSC Adv., 2020,10, 215-227
• 3. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 4. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 5. Aggregation-induced emission leading to two distinct emissive species in the solid-state structure of high-dipole organic chromophores?
  Felix Witte,Philipp Rietsch,Nithiya Nirmalananthan-Budau,Florian Weigert,Jan P. G?tze,Ute Resch-Genger,Siegfried Eigler,Beate Paulus Phys. Chem. Chem. Phys., 2021,23, 17521-17529

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates

Research Brief on 2-methyl-1-(propylsulfanyl)cyclobutane-1-carboxylic acid (CAS: 1504153-40-5): Recent Advances and Applications

2-methyl-1-(propylsulfanyl)cyclobutane-1-carboxylic acid (CAS: 1504153-40-5) has recently emerged as a compound of significant interest in the field of chemical biology and medicinal chemistry. This cyclobutane derivative, characterized by its unique structural features, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, biological activity, and potential as a scaffold for drug development. This research brief aims to summarize the latest findings and highlight the key advancements related to this compound.

The synthesis of 2-methyl-1-(propylsulfanyl)cyclobutane-1-carboxylic acid has been optimized in recent studies, with a focus on improving yield and purity. Researchers have employed advanced catalytic methods and green chemistry principles to achieve efficient and sustainable production. The compound's structural complexity, particularly the cyclobutane ring and the propylsulfanyl moiety, has posed challenges in synthesis, but recent breakthroughs have addressed these issues, enabling larger-scale production for further studies.

In terms of biological activity, preliminary investigations have revealed that 2-methyl-1-(propylsulfanyl)cyclobutane-1-carboxylic acid exhibits notable interactions with specific enzymatic targets. Recent in vitro studies have demonstrated its inhibitory effects on certain proteases and kinases, suggesting potential applications in oncology and inflammatory diseases. The compound's mechanism of action is currently under investigation, with early data indicating that it may act as an allosteric modulator or competitive inhibitor, depending on the target enzyme.

One of the most exciting developments is the exploration of this compound as a building block for novel drug candidates. Its rigid cyclobutane core provides a stable framework for structural modifications, while the carboxylic acid and sulfanyl groups offer sites for further functionalization. Recent medicinal chemistry efforts have focused on creating derivatives with enhanced pharmacokinetic properties and target specificity. Several patent applications have been filed in the past year, highlighting the pharmaceutical industry's growing interest in this chemical scaffold.

The compound's potential in drug delivery systems has also been investigated. Due to its amphiphilic nature, 2-methyl-1-(propylsulfanyl)cyclobutane-1-carboxylic acid has shown promise in forming stable micelles and liposomes. Recent studies have explored its use as a component in nanoparticle formulations for targeted drug delivery, particularly in cancer therapy. The compound's ability to improve solubility and bioavailability of hydrophobic drugs makes it an attractive candidate for formulation development.

Safety and toxicity profiles of 2-methyl-1-(propylsulfanyl)cyclobutane-1-carboxylic acid are currently being evaluated in preclinical studies. Early results suggest a favorable safety margin, with no significant adverse effects observed in animal models at therapeutic doses. However, comprehensive toxicological assessments are ongoing, including genotoxicity and chronic exposure studies, to fully characterize its safety profile before potential clinical applications.

In conclusion, 2-methyl-1-(propylsulfanyl)cyclobutane-1-carboxylic acid (CAS: 1504153-40-5) represents a promising compound with diverse applications in medicinal chemistry and drug development. Recent advances in its synthesis, biological evaluation, and formulation potential highlight its value as a research focus. As investigations continue, this compound may pave the way for novel therapeutic agents and delivery systems in the coming years. Researchers are encouraged to explore its full potential through collaborative efforts and interdisciplinary approaches.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)